Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
News, developments and strategies related to eClinical, data management, data collection, ePRO, and more information technology used in the drug development chain. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
|
|
The Hutchinson Sant? G-VIR? Glove Reduces the Risk of HIV Virus Transmission in Accidental Needlesticks by 99%, According to a Study Published in the Journal Surgery in February 2013[1]
Publish date: Feb 26, 2013
![]()
PR Newswire LIANCOURT, France, February 26, 2013 LIANCOURT, France, February 26, 2013 /PRNewswire/ --
The AIDS and hepatitis C viruses expose healthcare personnel to the risk of viral transmission (see the section Accidental
exposure to blood: the contamination risks for healthcare personnel) as a result of: To view the Multimedia News Release, please click:
http://www.multivu.com/mnr/58703-Hutchinson-Sante
Thanks to a new patented technology developed by Hutchinson Santé, an innovative player in the fight against infection
risks and in the comfort of healthcare personnel, the G-VIR® glove reduces the risk of contamination in cases of accidental
exposure to blood, as shown in the study published in the February edition of
Surgery
(read the opinion of Prof. Charles Edmiston, surgeon and epidemiologist
in - Milwaukee, United States-, co-author of
the article).
The G-VIR® is an active protection glove, designed and developed to improve protection for carers against the risks
of viral contamination. The G-VIR® is made up of 3 layers. The middle layer includes a disinfecting liquid dispersed
as micro-droplets (see: G-VIR®, innovative technology for protecting carers): in the case of an accidental puncture,
the disinfecting liquid is released on the inside and the outside of the sharp to inactivate the viruses.
The study presented in
Surgery
-
the abstract of which
is attached
-
is t
he first to test the efficacy of the G-VIR® in reducing the transmission of the AIDS virus - the studies
carried out up to now had assessed the G-VIR®'s performance on a number of model viruses, such as BVDV, FIV, and HSV1[
2] but never on HIV. 1. Charles E.Edmiston Jr: Evaluation of an antimicrobial
surgical glove to inactivate live human immunodeficiency following simulated glove puncture, Surgery 2013; 153:225-332. 2. Bovine Virus Diarrhoea Virus, feline immunodeficiency virus, herpes simplex
virus type 1
SOURCE Hutchinson Sante
|
|